Evidence map›Paper›PMID 43007468›Full record

ReviewMolecular biology reports2026

Research progress on ferroptosis in drug-induced kidney injury.

Ye Sun, Ziyi Shang, Aijia Cao, Chengcheng Zhao, Bowen Yang, Chunyang Fan, Qijia Ji, Zilong Chen, Chuanxin Liu, Xuejiao Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ye SunLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003, China.
Ziyi ShangLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003, China.
Aijia CaoDepartment of Pharmacy, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Chengcheng ZhaoSchool of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China.
Bowen YangLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003, China.
Chunyang FanLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003, China.
Qijia JiLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003, China.
Zilong ChenLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003, China.
Chuanxin LiuLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003, China. 15222003775@163.com.
Xuejiao LiLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Key Laboratory of Hereditary Rare Diseases of Health Commission of Henan Province, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, College of Clinical Medicine of Henan, University of Science and Technology, Luoyang, 471003, China. white_snow1987@163.com.

Funding

General Program of Henan Natural Science Foundation 262300421558the Henan Medical Science and Technology Research Project LHGJ20240427the Key Scientific Research Project Plan of Higher Education Institutions in Henan Provinc 26A350002
6 · The paper itself

Abstract

Ferroptosis is a novel form of programmed cell death that has garnered increasing attention in recent years in the study of drug-induced kidney injury, where it plays a critical role in the onset and progression of the disease. This review systematically summarizes the core mechanisms and regulatory pathways of ferroptosis in kidney injury, as well as the crosstalk between ferroptosis and other forms of programmed cell death. It further discusses how microbial-derived drugs, traditional Chinese medicines, and their active monomers induce renal ferroptosis through their respective core targets, thereby mediating drug-induced kidney injury. By synthesizing existing evidence, this paper clarifies the common patterns and key targets by which various drugs induce kidney injury via the ferroptosis pathway. It provides a theoretical foundation for drug safety evaluation, clinical medication risk early warning and targeted renal protection strategies, and also sheds new light on the exploration of combined medication schemes, indirect toxic mechanisms and individualized toxicity detection.

Indexed as

Acute Kidney InjuryFerroptosisAnimalsApoptosisDrugs, Chinese HerbalHumansKidneyMedicine, Chinese TraditionalDrugs, Chinese HerbalDrug-induced kidney injuryFerroptosisMicrobial-derived drugsRenal toxicologySynthetic drugsTraditional Chinese medicines

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.